Pipeline

Nucleoside metabolic pathway inhibitors to target DNA synthesis and cell proliferation

Targeted to p53 pathway:
The new molecule has been synthesized from a known micro nutrient and currently using drug combination is called schiff base reaction.This novel molecule was showed in vitro anti-cancer activity through targeting cancer and cancer stem cells in human pancreatic cancer cells.

Drug repurposing in oncology involved in identifying existing medications originally developed for other conditions and using them to treat cancer. This strategy accelerates drug development by utilizing compounds with known safety profiles, reducing costs and time compared to traditional drug discovery. By leveraging these existing therapies, we can expand treatment options, improve patient outcomes, and enhance the effectiveness of current cancer therapies.

DDR2 (Discoidin Domain Receptor 2) is a receptor tyrosine kinase that is activated by binding to collagen in the extracellular matrix.

Zonulin is a human protein that modulates the permeability of tight junctions between cells of the digestive tract.